Dogwood Therapeutics (DWTX) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
6 Nov, 2026Executive summary
Completed the 239-patient Halneuron® Phase 2b trial for chemotherapy-induced neuropathic pain (CINP); top-line results expected in November 2026.
Fully enrolled 95 patients in the 12-week open-label extension; completion expected in early 2027.
Cash of $4.9M at September 30 plus the $5.0M October placement is expected to fund operations through Q1 2027.
Financial highlights
Q3 licensing revenue was $100K, the first payment under the PRIDCor License Agreement; cost of goods sold was $88.1K and gross profit was $11.9K.
Q3 R&D expense was $3.3M vs. $14.5M YoY, primarily reflecting the prior-year $12.0M acquired IPR&D charge, partly offset by higher Halneuron® costs.
Q3 G&A expense was $1.6M vs. $1.3M YoY, primarily due to higher salaries and personnel costs.
Q3 operating expenses were $4.93M vs. $15.81M YoY; 9M expenses were $24.07M vs. $24.16M.
9M R&D expense fell to $9.27M from $19.53M, primarily reflecting the prior-year acquired IPR&D charge, partly offset by higher Halneuron® trial costs.
Outlook and guidance
Halneuron® Phase 2b CINP top-line results are expected in November 2026; final data from the 12-week open-label extension are expected in early 2027.
SP16 IV Phase 1b patient dosing is projected to begin in the coming months; the initial safety trial is funded by an NCI grant.
Cash and October placement proceeds are expected to fund operations through Q1 2027; additional financing is needed beyond that period.
Latest events from Dogwood Therapeutics
- A 4.1 million-share resale registration meets a concentrated ownership structure and clinical-stage risk.DWTX
Registration filing - Halneuron delivers significant, durable pain relief in cancer neuropathy with strong clinical progress.DWTX
Corporate presentation - A novel, scalable NaV1.7 inhibitor shows durable efficacy for chemotherapy-induced neuropathic pain.DWTX
KOL event - Q2 2026 net loss reached $11.5M as CINP trial nears completion; cash runway into Q4 2026.DWTX
Q2 2026 - Halneuron delivers significant, durable pain relief for cancer patients with a strong safety profile.DWTX
Corporate presentation - Halneuron® and SP16 advance as first-in-class non-opioid pain therapies targeting major unmet needs.DWTX
Corporate presentation - Pipeline advances, narrowed net loss, and cash runway into Q4 2026; more funding needed.DWTX
Q1 2026 - Halneuron® delivers significant pain relief in CINP, with pivotal data expected Fall 2026.DWTX
Corporate presentation - Halneuron and SP16 progress in clinical trials for chemotherapy-induced neuropathy and pain.DWTX
Study Update